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TCTP contains a BH3-like domain, 
which instead of inhibiting, 
activates Bcl-xL
Stéphanie Thébault1,2,*, Morgane Agez1,3,*, Xiaoke Chi4,5, Johann Stojko6, Vincent Cura1, 
Stéphanie B. Telerman7,8, Laurent Maillet9, Fabien Gautier9,10, Isabelle Billas-Massobrio1, 
Catherine Birck1, Nathalie Troffer-Charlier1, Teele Karafin2,3, Joane Honoré3,  
Andrea Senff-Ribeiro2,3, Sylvie Montessuit11, Christopher M. Johnson8, Philippe Juin9,10, 
Sarah Cianférani6, Jean-Claude Martinou11, David W. Andrews4,5, Robert Amson2,3,#, 
Adam Telerman2,3,# & Jean Cavarelli1,#
Translationally Controlled Tumor Protein (TCTP) is anti-apoptotic, key in development and cancer, 
however without the typical Bcl2 family members’ structure. Here we report that TCTP contains a BH3-
like domain and forms heterocomplexes with Bcl-xL. The crystal structure of a Bcl-xL deletion variant-
TCTP11–31 complex reveals that TCTP refolds in a helical conformation upon binding the BH3-groove of 
Bcl-xL, although lacking the h1-subregion interaction. Experiments using in vitro-vivo reconstituted 
systems and TCTP+/− mice indicate that TCTP activates the anti-apoptotic function of Bcl-xL, in contrast 
to all other BH3-proteins. Replacing the non-conserved h1 of TCTP by that of Bax drastically increases 
the affinity of this hybrid for Bcl-xL, modifying its biological properties. This work reveals a novel class of 
BH3-proteins potentiating the anti-apoptotic function of Bcl-xL.
Members of the Bcl2 family of proteins play a critical role in governing the cell death program1. This family of 
Bcl2 proteins can be functionally divided into the pro-apoptotic and anti-apoptotic proteins. They contain sub-
domains that are conserved to variable extend and are called BH domains, because of their homology to Bcl2 
(BH: Bcl2 homology domain). As referred to previously2, distant cousins of this family are termed BH3-only 
proteins and share the third homology domain, typically represented by Bid, Bim, Bad, Puma, Noxa and others as 
reviewed1. These BH3-only proteins are pro-apoptotic by either activating other pro-apoptotic proteins (Bax and 
Bak) or inhibiting the anti-apoptotic proteins (Bcl2, Bcl-xL, Mcl1, Bcl-w and A1). Hitherto, all known BH3-only 
proteins binding Bcl-xL inhibit its anti-apoptotic function by a well-established mechanism3, yet there are no 
BH3-proteins described activating Bcl-xL. Intriguingly the binding of these BH3-proteins to a very similar site on 
Bax results in the activation of its pro-apoptotic function. It remains completely unknown how the anti-apoptotic 
function of Bcl-xL could be potentiated.
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Translationally Controlled Tumor Protein (TCTP/tpt1) is a regulator of pluripotency4, the cancer stem cell 
compartment5, the tumor reversion program5–9, tumor progression5–9 and certain forms of inflammatory dis-
eases10. It was described as a pro-survival protein by potentiating both Mcl111,12 and Bcl-xL13 and antagonizing the 
P53 tumor suppressor5. It remains unknown how TCTP regulates Bcl-xL. The initial structural analysis of TCTP 
indicated that it was highly conserved through phylogeny and could be related to MSS4 without any link to pro-
teins of the Bcl2 family or any others involved in programmed cell death14. Given the importance in cancer of the 
anti-apoptotic proteins of the Bcl2 family15 of which Bcl-xL is a member and the focus on therapies that inhibit 
Bcl-xL, it becomes relevant to provide an understanding of any positive regulators of Bcl-xL.
Results
TCTP forms heterotetrameric complexes with Bcl-xL. By using extensive biochemical and biophys-
ical studies (Supplementary Figs 1–6) we show that TCTP forms heterotetrameric complexes with Bcl-xL via 
crucial interactions between the N-Terminal region of TCTP (TCTP11–31) and the BH3 binding groove of Bcl-xL. 
Bcl-xL-Y101K mutant, which cannot bind to BH3 domains16, was unable to form heterocomplexes with TCTP 
suggesting that the interaction is with the BH3 binding pocket on Bcl-xL. ABT-737, a molecule that specifi-
cally, and with high affinity, targets the BH3-groove, abrogated formation of the TCTP/Bcl-xL complexes. There 
was no complex formation between Bcl-xL and full-length TCTP-R21A N-terminal mutant. These results sug-
gest that the N-terminal part of TCTP has a BH3-like domain that interacts with the BH3-groove of Bcl-xL 
(Supplementary Figs 1–6).
TCTP contains a BH3-like domain. Surprisingly, aligning the amino-acid sequence of the N-terminal 
region of TCTP with BH3 domains from Bcl-2 family members revealed a putative BH3 domain in TCTP 
(Fig. 1A), suggesting that this region might bind Bcl-xL. Although the nature of the amino-acids in the h1 (P1) 
sub-region of the BH3 is not conserved in TCTP, the amino-acids in h2 (P2), h3 (P3) and h4 (P4), including 
I20, I23 and L27 are homologous to residues found in other BH3-domains that bind to the same hydrophobic 
Figure 1. TCTP contains a non-canonical BH3 domain interacting with the BH3 groove of Bcl-xL.  
(A) Sequence alignment of the N-terminal region of TCTP (h:human; m:mouse; d:Drosophila; y:yeast; p:plant) 
with other BH3 domain containing proteins. In red, the conserved hydrophobic residues of the BH3 domain 
(named h1 (P1), h2 (P2), h3 (P3) and h4 (P4)). In green, the GD signature of BH3 domains. In blue, the 
conserved charged residues. (B) Interaction between Bcl-xL and TCTP-BH3 peptides. Calorimetric titration 
between (left panel) Bcl-xL (0.065 mM) and increasing amount of TCTP-BH3 (1.39 mM); (middle panel) Bcl-
xL-Y101K (0.072 mM) and increasing amount of TCTP-BH3 (0.955 mM); (right panel) Bcl-xL (0.065 mM) 
and increasing amount of TCTP-BH3-R21A (1.26 mM). Each experiment was carried out at 30 °C in 50 mM 
ammonium bicarbonate pH 9. (C) In cellulo BRET analysis between TCTP and Bcl-xL, inhibition by ABT-737, 
lack of binding for the R21A TCTP to Bcl-xL (left panel) and Bax (right panel).
www.nature.com/scientificreports/
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groove of Bcl-xL. This putative Bcl-xL-binding domain of TCTP also contains a signature (Gly/Ala)-Asp motif 
between the h3 (P3) and h4 (P4) positions (Fig. 1A), suggesting that this region of TCTP could interact with the 
BH3-binding pocket of Bcl-xL.
TCTP’s BH3 domain recognizes the BH3 groove of Bcl-xL. Isothermal Titration Calorimetry (ITC) 
(Fig. 1B) shows that TCTP11–31 peptide, containing the putative BH3-domain, binds to Bcl-xL with a dissociation 
constant of 12 μ M. As controls for this interaction, we used two mutants: TCTP11–31-R21A and Bcl-xL-Y101K. 
TCTP11–31-R21A does not bind to Bcl-xL, and Bcl-xL-Y101K does not bind TCTP11–31 (Fig. 1B). To provide 
evidence that this interaction between full-length TCTP and Bcl-xL occurs at the cellular level, we measured the 
close proximity between transiently transfected Luciferase-fused TCTP and YFP-fused Bcl-xL by biolumines-
cence resonance energy transfer (BRET). As shown in Fig. 1C left panel, saturable BRET signals were observed 
between donor wild type TCTP and increasing levels of acceptor wild type Bcl-xL, indicative of a specific interac-
tion between these proteins. In contrast, we detected no specific BRET signals between donor TCTP and accep-
tor, YFP-fused BAX, suggesting a lack of interaction between these two proteins (Fig. 1C right panel). BRET 
signals between TCTP and Bcl-xL were significantly inhibited by treatment of cells with the BH3 mimetic ABT-
737 (Fig. 1C left panel), supporting the notion that the interaction relies on the BH3-binding groove of Bcl-xL. 
Further consistent with this, the R21A mutation in TCTP abrogated BRET signals between full-length TCTP and 
Bcl-xL (Fig. 1C left panel). Together these results suggest that BH3-TCTP binds to the BH3 groove of Bcl-xL.
Crystal structure of Bcl-xL bound to BH3 domain of TCTP. To provide structural details of the TCTP/
Bcl-xL interaction, the crystal structure of a deletion variant of Bcl-xL (Bcl-xLΔ 27–81Δ TM) in complex with 
TCTP11–31 has been solved and refined at 2.1 Å (Fig. 2A,B, Supplementary Fig. 7 and Table 1). This crystal struc-
ture revealed that upon binding to Bcl-xL, the residues 16–27 of TCTP11–31 completely refold into a 3 turn α -helix 
conformation that binds to the BH3-binding pocket of Bcl-xL, a hydrophobic groove created by helices α 2-α 5 
Figure 2. Crystal structure of Bcl-xL: TCTP-BH3 complex. (A) Surface diagram showing the interface 
between Bcl-xL and the TCTP-BH3 peptide. Bcl-xL is in the surface representation. The hydrophobic residues 
are drawn in yellow, positively charged residues in blue, the negatively charged residues in red, and other in 
white. The TCTP-BH3 peptide is represented in cartoon and colored in orange. Side chains of residues involved 
in the binding interface are represented as stick models. (B) Cartoon representation of truncated Bcl-xL bound 
to TCTP-BH3 domain. Two close views (left and right panel) of the interactions at the interfaces between one 
TCTP-BH3 peptide and the canonical BH3 groove of Bcl-xL. Residues involved in the interface are indicated 
and drawn stick models.
www.nature.com/scientificreports/
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of Bcl-xL (Fig. 2A,B). In unbound TCTP17, this N-terminal region stabilizes the β -sheet hydrophobic core of the 
entire TCTP protein (Supplementary Fig. 9). This suggests that the interaction between the full size Bcl-xL and 
TCTP proteins induces a substantial reorganization of the known TCTP fold.
The main difference in the binding of TCTP to the Bcl-xL groove as compared to other high affinity BH3 pro-
teins such as Bax is the absence of the first turn of the helix, located just before the canonical h1 (P1) motif which 
is non-conserved in TCTP. The functional relevance of this is addressed in the final part of this work in which this 
region of TCTP was replaced by the h1 subdomain of Bax.
As observed in complexes of Bcl-xL and other BH3 peptides18–24, the interaction between Bcl-xL and the BH3 
domain of TCTP is mediated by both hydrophobic and electrostatic interactions (Fig. 2A,B). The side chain of the 
hydrophobic residues at the h2 (P2, I20), h3 (P3, I23) and h4 (P4, L27) positions form a network of van der Waals 
interactions with the Bcl-xL groove (Fig. 2A,B, Supplementary Figs 7,8). Three additional residues, I17, L29 and 
the side chain of K19 participate in this hydrophobic packing. Of note, since the canonical h1 (P1) is missing in 
TCTP, I17 might counterbalance this absence by packing with the hydrophobic residues F97, Y101, F105, L108, 
V126, V141, F146 and Y195 of Bcl-xL in the target-binding pocket formed by helices α 2-α 5. Furthermore sev-
eral hydrogen bonds and two salt bridge interactions contribute to the recognition process: (i) R21 of TCTP BH3 
domain interacts with E129 and D133 in Bcl-xL; and (ii) D25, part of the (Gly/Ala)-Asp motif between the h3 
(P3) and h4 (P4) positions of BH3 domain (Fig. 2A), interacts with R139 in Bcl-xL. These results explain the lack 
of binding of the TCTP-R21A mutant described above.
Data collection
X-ray source ESRF ID29
Wavelength (Å) 0.97625
Data collection temperature (K) 100
Detector Pilatus 6MF
Crystal-detector distance (mm) 383.18
Total rotation range (°) 180
Exposure range (°) and time (s) per image 0.1, 0.04
Mosaicity (°) 0.474
Cell parameters (Å) a = 100.36, b = 100.36, c = 105.04, α = β = γ = 90°
Space group P41212
Resolution range (outer shell) (Å) 46.50-2.10 (2.23–2.10)
Total number of reflections 404573 (61254)
Number of unique reflections 31973 (4976)
Completeness (%) 99.7 (98.4)
Multiplicity 12.7 (12.2)
< I/σ (I)> 19.2 (1.1)
Rmerge 0.074 (2.2)
Rmeas 0.077 (2.320)
CC1/2 0.999 (0.436)
Refinement
 Resolution range (Å) 37.45 − 2.10 (2.174 − 2.10)
 R-work/R-free 0.185 (0.347)/0.221 (0.361)
 Number of atoms 3444
 Protein; ligands; water 3377; 10; 57
 Protein residues 418
 RMS deviations from ideal bond lengths (Å)* 0.003
 RMS deviations from ideal bond angles (°)* 0.77
 Ramachandran favored (%) 98
 Ramachandran outliers (%) 0
 Average B-factor (Å2) 69.10
  macromolecules; ligands; solvent 69.2; 88.10; 59.10
Molprobity Validation
 Rotamer and C-beta outliers 0.3%; 0.
 Clashscore and Overall score 2.42; 1.01
Table 1.  X-ray Crystallographic Data collection and structure refinement statistics. †mean I/σ (I) falls below 
2.0 in the outer shell at 2.2 Å. Rmeas is the redundancy-independent merging R factor. Highest resolution shell is 
shown in parenthesis.
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In vitro and in vivo relevance of TCTP BH3 in regulating membrane permeabilization and the 
apoptotic process. We further tackled the control that TCTP exerts on Bcl-xL in inhibiting Bax, using 
respectively an in vitro reconstituted system (Fig. 3A–E), then purified mitochondria (Fig. 3F) and thymocytes 
from TCTP+/− haploinsufficient mice (Fig. 3G). To test the hypothesis that TCTP binding directly to Bcl-xL mod-
ifies Bcl-xL function, the impact of TCTP on membrane permeabilization was assayed using a well-established in 
vitro system in which purified recombinant proteins are used to permeabilize liposomes (Fig. 3, Supplementary 
Figs 10,11, Method summary and statistical analysis, Supplementary Table 2–4)25,26. This purified assay sys-
tem measures direct interactions in which full-length untagged Bcl-xL inhibits permeabilization by binding 
full-length caspase 8 cleaved Bid (cBid) and/or full-length untagged Bax, thereby preventing Bax oligomerization 
in membranes26. To assess the effect of TCTP on Bcl-xL binding directly to Bax we used a mutant Bid (cBidmt1) 
Figure 3. TCTP potentiates Bcl-xL inhibition of Bid/Bax. (A–E) in vitro reconstitution assay on liposome 
permeabilization. Increasing concentrations of Bcl-xL were incubated in different molecular ratios [Bcl-
xL:TCTP] with TCTP WT (A,C) or with a fixed amount of TCTP R21A (B,D) at pH 9 for 45 min at 37 °C, 
as specified. The treated Bcl-xL was then added to reactions containing ANTS-DPX liposomes, 100 nM Bax 
and 20 nM of either cBid (A,B) or cBidmt1(C,D) at pH 7. Liposome permeabilization was quantified by 
fluorescence after 5h incubation at 37 °C where 100% release was defined as the fluorescence change due to lipid 
solubilization with 1% Triton X-100. Control reactions demonstrating that TCTP had no measureable effect 
on the function of any of the proteins other than Bcl-xL contained 320 nM pH9 treated TCTP ANTS/DPX 
liposomes, 100 nM Bax and 20 nM of cBid or cBidmt1 as indicated (E). Error bars, std. dev. n = 3. To compare 
between the TCTP treated groups and the Control group statistically, two-way ANOVA test was performed 
for (A–D) and one-way ANOVA test was performed for (E). Dunnett’s multiple comparisons test was used to 
calculate the significance of difference between the TCTP treated groups and the corresponding control group 
(No TCTP for (A–D), cBid+ Bax or cBidmt1+ Bax for E). Colored asterisks above each data point indicate the 
statistical significance (*p < 0.05; **p < 0.01, no asterisks if p ≥ 0.05). A complete statistical analysis is provided 
in Supplementary Table 2–4. (F) Permeabilization assays of mitochondrial membrane by tBid and Bax assessing 
cytochrome c release. Sub-optimal amounts of Bcl-xL were added as to inhibit only partially Bax mediated 
cytochrome c release. Bcl-xL and variants of TCTP were pre-incubated (TCTP ranging from 1.5–6μ M and 
3 μ Μ Bcl-xL framed in gray with red asterisk to highlight the pre-incubation), pH 9, 30 °C then added to the 
mitochondria at the concentration displayed in the figure. Cyto c intra-mito: mitochondrial fraction. Cyto c 
extra-mito: in the supernatant, analysed by Western blot. Similar conditions were used for mutant TCTP R21A 
protein. (G) Rescue of TCTP+/− haploinsufficiency: Thymocytes from TCTP+/− mice were γ -irradiated (γ -irr) 
(2.5 Gy) and cultured with WT TCTP protein or mutant R21A TCTP at concentrations 0 to 1000 nM.
www.nature.com/scientificreports/
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that binds and activates Bax but does not bind stably to Bcl-xL25,26. In these assays liposome permeabilization 
by activated Bax releases the entrapped fluorophore/quencher pair 8-aminonaphthalene-1,3,6-trisulfonic acid 
(ANTS)/p-xylene-bispyridinium (DPX), resulting in a measurable increase of fluorescence. Recombinant 
TCTP enhanced Bcl-xL inhibition of both cBid/Bax and cBidmt1/Bax-mediated liposome permeabilization in a 
dose-dependent manner (Fig. 3A,C). As expected, in control experiments the TCTP R21A mutant protein had no 
effect on Bcl-xL activity (Fig. 3B,D). In control experiments designed to determine if TCTP affected the activity of 
cBid/cBidmt1-Bax induced membrane permeabilization, TCTP had no effect in reactions not containing Bcl-xL 
(Fig. 3E). Similar results were obtained using TCTP11–31 or TCTP11–31 R21A mutant peptides demonstrating that 
the putative BH3 region in TCTP is sufficient to activate Bcl-xL (Supplementary Figs 10, 11, Method summary 
and statistical analysis, supplementary Table 2–4). Taken together these results suggest that TCTP potentiates 
Bcl-xL function by increasing its interaction with Bax, and possibly also with Bid, without interfering with 
Bid-mediated activation of Bax.
To examine whether TCTP potentiates the anti-apoptotic effect of Bcl-xL against Bax at the mitochon-
drial level, we reconstituted the system with purified mitochondria27. When the release of cytochrome c 
is used as a probe for Bax activity on these mitochondria, we found that wild type TCTP protein (Fig. 3F) 
and peptide TCTP11–31 (Supplementary Fig. 12), in the presence of Bcl-xL, inhibit cytochrome c release in 
a concentration-dependent manner (Fig. 3F, Supplementary Fig. 12). TCTP R21A mutant protein (Fig. 3F), 
TCTP R21A full-length and peptide mutants (Supplementary Fig. 12) or a truncated TCTP peptide (TCTP1–20) 
(Supplementary Fig. 12), do not potentiate Bcl-xL.
TCTP deficient mice were used to investigate the biological relevance of this interaction in vivo. TCTP 
knock out mice are embryologically lethal (E 6.5–7) due to increased cell death5,17,28, however heterozygous 
animals are viable but haploinsufficient5. Typically, the thymocytes of these animals are more sensitive to 
γ -irradiation5. Thymocytes from irradiated TCTP+/− mice were assessed for their viability in complementation 
assays in which either TCTP protein or peptide were added. Both, WT TCTP protein (Fig. 3G) and TCTP1–31 
peptide (Supplementary Fig. 13), containing the BH3 domain, rescue completely the TCTP+/− haploinsuffi-
cient phenotype, reducing the sensitivity to apoptosis to that found in thymocytes of wild type animals (Fig. 3G, 
Supplementary Fig. 13). This anti-apoptotic function of TCTP is absent in R21A mutants (Fig. 3G, Supplementary 
Fig. 13). The above experiments were done by taking advantage of the fact that TCTP contains in its NH2 ter-
minus a protein transduction domain (PTD) with the amino-acid sequence MIIYRDLISH 29–31. However, all 
previous experiments were always performed on cell lines and not on cells directly derived from organs. It is 
therefore completely justified to examine how much of the full-length protein (either WT or mutant) or peptides 
(WT, mutant and hybrid) are penetrating efficiently irradiated thymocytes directly derived from mice, as it is the 
case in the present study. In all our constructs, the PTD was placed at the NH2 end of the peptide to be trans-
duced in order to leave the PTD intact and the FLAG sequence was fused C-terminally. The results are shown 
in Supplementary Figure 14 and illustrate how efficiently TCTP full-length protein and peptides WT, mutant or 
hybrid are penetrating the irradiated thymocytes. The concentration used for the imaging necessitated higher 
amounts of peptides than the biological assays which are clearly much more sensitive. The double labeling using 
rabbit anti-FLAG revealed by anti-rabbit-FITC (Supplementary Fig. 14D) gives a higher background than direct 
labeling with anti-FLAG phyco-erythrin (Supplementary Fig. 14E-F), but both methods showed that WT or 
mutant TCTP peptides are equally efficiently incorporated into γ -irradiated thymocytes.
Thus in different experimental systems such as liposomes, purified mitochondria and in ex-vivo cell assays 
using TCTP+/− haploinsufficient mice, binding of the BH3-region of TCTP to Bcl-xL inhibits more efficiently 
Bax-mediated membrane permeabilization than does Bcl-xL alone.
Functional regulation of apoptosis by the non-canonical h1 (P1) sub-region of TCTP’s BH3. 
Based on the structural data outlined above, it appears that the h1 (P1) sub-region in the BH3- domain of TCTP 
is not conserved and is not folded as in some of the other known BH3 proteins. This h1 (P1) sub-region from 
different BH3 family proteins was suggested to be functionally important32. We therefore replaced the h1 (P1) 
sub-region of BH3-TCTP by that of Bax (Fig. 4A). The Bax peptide binds with relatively high affinity resulting 
in a measured dissociation constant (Kd) of 200 nM to Bcl-xL, the hybrid TCTP peptide containing the Bax h1 
(P1) sub-region has a similar Kd of 500 nM, both of which are much lower than 10–15 μ M Kd measured for WT 
TCTP (Fig. 4B).
Replacing the h1 subdomain of TCTP by the one found in Bax completely abrogated its anti-apoptotic func-
tion when used in a complementation assay with irradiated TCTP+/− haploinsufficient thymocytes, suggesting 
that this region confers, to a large extent, the anti-apoptotic properties of TCTP’s BH3 domain (Fig. 4C). Taken 
together, these results for the affinities measured by ITC for complexes between WT TCTP/Bcl-xL, Bax/Bcl-xL 
and the hybrid Bax(h1)-TCTP/Bcl-xL, underline the relevance of the non-canonical h1-subdomain in TCTP.
Discussion
For three decades, there has been converging evidence accumulated for the role played by members of the Bcl2 
family in regulating cell death during development, in physiological processes and in diseases, of which most 
prominently cancer33–40. However, the positive regulation and enhancement of the anti-apoptotic function of 
Bcl-xL remains mostly ignored41. In the present study, we report biochemical, structural and biological evidence 
that underlie this positive regulation of Bcl-xL by TCTP. TCTP is a major anti-apoptotic protein that exerts its 
activity on one side by direct binding to Bcl2 family members Mcl1 and Bcl-xL11–13 and on the other side by 
engaging into a reciprocal negative feedback loop with p535. This interaction between the N-terminal region and 
the BH3 domain of Bcl-xL was previously reported, however it was not anticipated at that time by what mech-
anism this N-terminus of TCTP binds to Bcl-xL13. Thus, at least two major apoptotic pathways are regulated by 
TCTP, namely the anti-apoptotic Bcl2 family Bcl-xL and Mcl111–13,42, and the pro-apoptotic p535. In line with this, 
www.nature.com/scientificreports/
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it was also described that reprogramming of cancer cells into revertants, which lost the malignant phenotype, 
parallels a drastic decrease of TCTP6–9,43. Also, the most aggressive forms of breast cancer have highly elevated 
levels of TCTP. Normal and cancer breast stem cells have an elevated level of TCTP that warrants their survival, 
and knocking down TCTP decreases the mammosphere-forming efficiency5. All these processes are closely inter-
connected with programmed cell death.
In this paper, we show that TCTP forms a heterotetramer with Bcl-xL and we extensively characterized these 
complexes using biochemical and biophysical methods. We reveal that the formation of the TCTP/Bcl-xl complex 
is governed by a BH3-like domain present in the N-terminal part of TCTP. The high resolution crystal structure 
of the purified BH3-TCTP/Bcl-xL complex highlights a substantial refolding/reorganization of the known TCTP 
fold and reveals at the atomic level how TCTP interacts with the BH3-binding groove of Bcl-xL. Mutational anal-
ysis of either the Bcl-xL BH3-binding groove or TCTP supports the structural data and confirms the specificity 
of this recognition process. Our data suggest that the interaction between the full size Bcl-xL and TCTP proteins 
should probably induce a substantial reorganization of the known TCTP fold. A reorganization of Bcl-xL folding 
is also expected, as upon binding to the TCTP BH3 peptide, helix α 2 of Bcl-xL elongates and this elongation is 
Figure 4. Molecular/functional analysis of the h1 (P1) subregion of BH3-TCTP. (A) The three BH3 peptides 
(TCTP in blue, Bax in red and the hybrid Bax/TCTP aligned with the h1 subregion framed). (B) Interaction 
between Bcl-xL and TCTP-BH3, or Bax or hybrid Bax/TCTP peptides. Calorimetric titration between Bcl-xL 
(0.043 mM) and increasing amount of TCTP-BH3 (0.75 mM) (blue curve); Bcl-xL (0.006 mM) and increasing 
amount of Bax (0.117 mM) (red curve); Bcl-xL (0.043 mM) and increasing amount of hybrid Bax/TCTP 
(0.65 mM) (black curve); Each experiment was carried at 30 °C in 50 mM ammonium bicarbonate pH 9.  
(C) Thymocytes from TCTP+/− mice were γ -irradiated (γ -irr) (2.5 Gy) and cultured in the presence of WT 
TCTP1–31 peptide, hybrid Bax/TCTP peptide at the indicated concentrations ranging from 0 to 1000 nM.  
(D) Schematic representation of the TCTP/Bcl-xL interaction in the context of the reciprocal feedback loop 
between P53 and TCTP, sequestering of P53 by Bcl-xL and the control of Bax.
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accompanied by the flipping of F105 outwards to form a hydrophobic groove that can accommodate the binding 
of the BH3 peptide, while Y101 is completely buried into the core hydrophobic interface with TCTP BH3 pep-
tide. Examples of a change of conformation of Bcl-xL induced by BH3 binding have been reported. Indeed, BH3 
mimetic treatment impacts on Bcl-xL localisation25. Moreover, PUMA-BH3 binding to Bcl-xL partially unfolds 
it in such a way that its interaction with p53 via a second and distinct site is affected23. Whether this extends to 
TCTP-BH3 binding to Bcl-xL requires further investigation. In all cases these data and the present work illustrate 
how secondary structure refolding of proteins, as reported for the widely-known examples of prion proteins44 
and few others examples, may be a key event in biology, modulating the conformation of proteins in the cell and 
generating different active and functional states45,46.
This regulation of the anti-apoptotic process by the BH3 domain of TCTP was further corroborated in in 
vitro reconstituted systems, where the sole presence of Bax, Bid or Bim, Bcl-xL and TCTP is clearly sufficient to 
control membrane permeabilization. This was further confirmed on purified mitochondria and for both of these 
systems a mutation is the BH3 domain of TCTP abrogated its function. This was ultimately evidenced on TCTP 
heterozygous haploinsufficient mice in which after γ-irradiation, the apoptosis process is rescued by wild type 
TCTP protein or peptide but not anymore by the mutant. We also tried to understand where resides the major 
difference between the binding of a negative pro-apoptotic regulator such as Bax and a positive regulator such as 
TCTP with regard to their respective interaction to Bcl-xL. Bax binds with a much higher affinity to Bcl-xL than 
TCTP does, and a hybrid mutant where the h1 subregion of TCTP was replaced by this domain from Bax results 
in a total loss of the positive regulation of Bcl-xL by TCTP. This hybrid mutant was not able anymore to rescue the 
haploinsufficient phenotype TCTP+/− murine thymocytes following γ-irradiation.
Our data highlight how subtle changes between two BH3 domains, more specifically here in the 
h1-subdomain, resulting in only a slight difference in the mode of recognition with the BH3 groove of Bcl-xL, 
reveal a significant increase in binding affinity, hence completely modifying the biological outcome. Combined 
with the structural analysis (Fig. 2A,B) where this region folds differently into Bcl-xL, these results might suggest 
a model wherein a rapid exchange of proteins bound to Bcl-xL occurs in favor of Bax/Bcl-xL complexes and, as 
such, TCTP could prime and activate Bcl-xL against Bax. It should be borne in mind that in exponentially grow-
ing cells or cancer cells where apoptosis is inhibited, TCTP levels are extremely high, even above actin47, and that 
in such conditions low affinity of TCTP/Bcl-xL would be compensated by abundance.
Altogether our results demonstrate that TCTP contains a non-canonical but functional BH3-domain that 
binds to -and unexpectedly activates- the anti-apoptotic function of Bcl-xL. We speculate that activation is 
achieved by virtue of the low affinity of the interaction as mutations that increase the affinity of the interaction 
abolish the activity of TCTP. Perhaps, the BH3-TCTP competes with Bcl-xL H9 for the BH3-binding pocket on 
Bcl-xL, partially activating Bcl-xL. It would not be surprising if other proteins with non-canonical BH3 peptides 
potentiating the anti-apoptotic effect of specific Bcl2 family members were identified. That BH3-proteins can 
either increase or decrease the activity of Bcl-xL increases the complexity of the system but also highlights the 
potential for identification of new therapeutic targets which would not only “hit” the anti-apoptotic proteins 
but also positive BH3-like regulators. Our demonstration of the interplay between TCTP and Bcl-xL might also 
shed a new light on the effects of TCTP on p53, of which Bcl-xL is a binding partner5,48. This might connect 
Bcl-xL and p53 to the regulation of other processes regulated by TCTP, such as cell shape and migration. Of 
note, it is known that TCTP interacts with the cytoskeleton49, more specifically with centrosomes and indirectly 
with microtubules50. Moreover, the inverse correlation between TCTP/RhoA and p53/cyclin A/actin expression 
suggests a common regulation for those proteins and their pathways51. TCTP is also implicated in the epithelial 
to mesenchymal transition31. From a more comprehensive perspective, accumulating knowledge suggest that 
TCTP functions as a “smart linker” unifying, regulating and ultimately defining the outcome of a wide variety 
of biological processes ranging from pluripotency to cell shape, cell death, tumorigenicity and tumor reversion. 
It exerts its function on a range of target-proteins and the data presented here indicate that both TCTP and the 
target -at least for TCTP/Bcl-xL- undergo major structural modifications which are probably at the basis of such 
a widespread biological effect of TCTP.
Methods
Constructs expression and mutagenesis. For expression as a GST-fusion protein, TCTP was cloned 
into a pHGGWA plasmid52 using the GatewayTM Technology (Invitrogen). The TCTP gene was amplified by 
PCR and cloned into a pDONR207 plasmid by BP reaction and then subcloned into pHGGWA plasmid by the LR 
reaction as described in Busso et al.52. See Supplementary Information for full details.
Bioluminescence resonance energy transfer (BRET). BRET assays were performed as indicated in Bah et al.41. See 
Supplementary Information for full details.
Protein expression and purification. See Supplementary Information for full details.
Peptides used for in vitro assays and in vivo assays. See Supplementary Information for full details.
Complementation experiments. In order to complement the haploinsufficient TCTP+/− mice with exog-
enous TCTP, we took advantage of the fact that the first N-terminal fragment of TCTP functions as a Protein 
Transduction Domain (PTD), enabling TCTP to penetrate into the cell (Supplementary Figs 13–14D) by a mech-
anism hitherto not well understood30,53–55. Thymocytes from wild type or TCTP+/− mice were irradiated (2.5 Gy 
of γ-irradiation) and cultured overnight in the presence of TCTP protein (Wild type or mutant TCTP protein 
bearing the mutation R21A) or TCTP peptide (wild type TCTP peptide 1–31, mutant TCTP peptide bearing the 
mutation R21A, or peptide 1–20) at concentrations ranging from 0–1000 nM.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:19725 | DOI: 10.1038/srep19725
Isothermal Titration Calorimetry experiments. Titrations were done by isothermal titration calorime-
try (ITC) assays using an ITC200 calorimeter from GE-Microcal. See Supplementary Information for full details.
Crystallization, X-ray data collection, structure determination, and refinement. 
High-throughput crystallization screening was performed using a Mosquito liquid transfer robot (TTP Labtech) 
and the sitting-drop vapor diffusion method. Crystals were obtained at 20 °C by mixing 0.2 μ L of reservoir solu-
tion (100 mM Pipes pH 7, 1.5M Tris-sodium citrate) with 0.2 μ L of 300 μ M of Bcl-xL (Δ 27–81Δ CT) + 1 mM 
TCTP11–31 solution in buffer containing 50 mM ammonium bicarbonate pH 9.3 and by equilibrating the mixture 
against 40 μ l of reservoir solution. A 2.1 Å resolution data set was collected at 100 K on beamline ID29 at the 
European Synchrotron Radiation Facility with a Pilatus 6MF detector. The crystal belongs to space group P41212 
with unit cell dimensions a = 100.36 Å, b = 100.36 Å, c = 105.04Å and α = β = γ = 90°. Diffraction data were 
processed, integrated, and scaled with XDS56 and HKL200057. The structure of human Bcl-xL/TCTP11–31 complex 
was solved by molecular replacement using the program Phenix58 and coordinates from the human Bcl-xL-Beclin 
complex (Protein Data Bank code 2P1L20) as a search model. The model was built with Coot59 and refined with 
Phenix58 and Buster60. The statistics are summarized in Table 1. See Supplementary Information for full details. 
Coordinates of the refined structural model and structure factors have been deposited to the Protein Data Bank 
(PDB) with the accession code 4Z9V.
Interaction experiments. When not specified, proteins tested for binding experiments were mixed at 100 μ M, 
dialyzed against 10 mM CHES pH 9, 50 mM NaCl, 1 mM DTT or TCEP, depending on the analysis, and heated 
overnight at 30 °C.
Gel filtration. For binding experiments, 100 to 200PL of protein mixture were loaded on a size exclusion chro-
matography (S200, GE Healthcare) column, while elution profiles were measured by UV absorption at 280 nm.
Size-Exclusion Chromatography coupled to Multi-Angle Light Scattering (SEC-MALS). 
SEC-MALS experiments were performed on a multi-angle light scattering detector (miniDAWN TREOS, 
Wyatt Technologies) coupled in-line with SEC and an interferometric refractometer (Optilab T-rEX, Wyatt 
Technologies). See Supplementary Information for full details.
Native mass spectrometry. Prior to any mass spectrometry experiment, protein buffer was exchanged twice 
against a 50 mM ammonium acetate (NH4Ac) solution at pH 9.0 using microcentrifuge gel filtration columns 
(Zeba 0.5 ml, Thermo Scientific, Rockford, IL). Protein concentration was determined spectrophotometrically. 
NanoESI-MS measurements were carried out on an electrospray quadrupole-time-of-flight mass spectrometer 
(Synapt G2 HDMS, Waters, Manchester, UK) equipped with an automated chip-based nanoESI source (Triversa 
Nanomate, Advion Biosciences, Ithaca, NY) operating in the positive ion mode. See Supplementary Information 
for full details.
in vitro system. purified recombinant proteins are used to permeabilize liposomes as described before25,26. See 
Supplementary Information for full details.
Cytochrome c release assay. Mitochondria from mouse liver were purified as described by Eskes et al.61. See 
Supplementary Information for full details.
All experiments were performed in accordance with relevant guidelines and regulation. All experimental 
protocols described in this paper were approved by CNRS and INSERM. All animal studies were carried out in 
the restricted facilities provided by the CNRS, INSERM and Institut Gustave Roussy, by authorized personnel 
following the prescribed rules.
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